Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 11/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.44 |
| ▸ | TUBB | P07437 | 2/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2373289 | 1.00 | APP (0.67) | APPKDM4EMEN1LMNATTR | |
| SCHEMBL2374986 | 0.88 | APP (0.71) | APPKDM4EMEN1LMNATTR | |
| SCHEMBL2374973 | 0.88 | APP (0.71) | APPKDM4EMEN1LMNATTR | |
| SCHEMBL2374723 | 0.81 | APP (1.00) | APPKDM4EMEN1LMNATTR | |
| SCHEMBL2374726 | 0.81 | APP (1.00) | APPKDM4EMEN1LMNATTR | |
| SCHEMBL2373284 | 0.79 | APP (0.41) | APPLMNATP53KMT2ASMN1; SMN2 | |
| SCHEMBL2374125 | 0.79 | APP (1.00) | APPMAPT | |
| SCHEMBL2373704 | 0.79 | APP (1.00) | APPMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2373698 | 0.79 | APP (1.00) | APPMEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL2374135 | 0.79 | APP (1.00) | APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363392-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-1999109-B1 | STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES | UNIV PENNSYLVANIA (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2363391-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2363392-A1 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | The Trustees of The University of Pennsylvania (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7687052-B2 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038195-A1 | radiolabeling; neurodegenerative diseases | APP, PSEN1, HTT | APP 1/4885KDM4E 3593/4885MEN1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.